The Future of Longevity: Dr. David Luu Joins Noom’s Board to Drive Global Health Innovation
Slice of Healthcare Team
06/09/2025
Introduction
In a bold move to strengthen its commitment to personalized, preventative healthcare, Noom has announced the appointment of Dr. David Luu to its Board of Directors. A visionary cardiac surgeon and longevity medicine pioneer, Dr. Luu brings decades of experience in integrating advanced medical technologies and global health initiatives. As he joins Noom’s mission to help everyone live better longer, Dr. Luu shares his strategic vision for longevity care, global outreach, and the role of technology in the future of healthcare—alongside insights from Noom’s CEO, Geoff Cook.
Slice of Healthcare had the opportunity to sit down with both Dr. Luu and Geoff Cook to explore how this partnership will shape the future of longevity medicine and accessible health solutions.
Strategic Vision and Longevity Medicine
Slice of Healthcare: You’ve founded several health-tech initiatives, including Longevity Docs and Juisci. How do you plan to leverage your expertise in evidence-based longevity medicine to influence Noom’s approach to chronic disease prevention?
Dr. David Luu: As the founder of Longevity Docs, the global network for longevity physicians, I am privileged to have access to the latest in longevity medicine and research, as well as an incredible professional community of doctors whose life missions are to help people age well. Noom’s preventative health platform is poised to deliver tremendous impact to healthspan. I’m excited to be able to lend my network and expertise in longevity medicine to Noom’s core mission of empowering everyone, everywhere to live better longer.
Slice of Healthcare: Based on your deep experience as a longevity medicine doctor and innovator, what do you see as some of the biggest opportunities for Noom to improve access to next-generation life-extending care?
Dr. David Luu: Noom is today a leader in one of the most challenging aspects of medicine: combining effective clinical treatments with ongoing lifestyle support. Noom has shown tremendous ability to quickly incorporate therapies like GLP-1s and estrogen HRT, which have significant evidence on overall health – with more coming on longevity each day. I’m also excited to partner with Noom on the evolving landscape of therapies. But perhaps most importantly, Noom has a proven ability to democratize access, helping connect millions of people to personalized programs, education, and health impact.
Slice of Healthcare: Why is longevity medicine important?
Dr. David Luu: Longevity medicine matters because it shifts our focus from simply treating disease to nurturing the biology of health, years before the first symptom ever appears. As a cardiac surgeon, I saw too many lives saved one emergency at a time. As a longevity doctor, I can help people avoid the operating room altogether by combining rigorous science, advanced diagnostics, and daily habits that compound over decades. It’s not about chasing immortality or bio-hacks; it’s about democratizing the knowledge and tools that let each of us add vibrant, purposeful years to our lives.
Slice of Healthcare: Why is now the right time for longevity medicine to go mainstream?
Dr. David Luu: We are in a moment of unique opportunity. We have a rapidly aging population – more than 3.5 million people turn 65 in the US each year, and as a share of overall population, the 65+ group is projected to increase by 33% by 2050. We have growing consumer interest and appetite for solutions that support them, no matter what age they are today, preparing for a long and healthy future. We have a boom in research and clinical applications that demonstrate huge potential. Noom is perfectly positioned to support and meet this need.
Technology-Driven Healthcare Solutions
Slice of Healthcare: As a physician-entrepreneur, you’ve integrated AI and precision medicine in your ventures. How do you envision incorporating these advanced technologies into Noom’s personalized health programs?
Dr. David Luu: Noom is already at the forefront of bringing AI and precision medicine tools to their users. I’m impressed by Noom’s thoughtful approach to strategic partnerships that has brought the latest technology to their users’ fingertips – including body composition analysis and body age prediction. I’m looking forward to getting plugged into conversations at Noom about how we are going to leverage AI and precision medicine to bring best-in-class programs to consumers who are looking for amazing longevity tools!
Slice of Healthcare: In your role as an advisor at Mount Sinai Icahn School of Medicine, you’ve been involved in AI, robotics, and nanomedicine. Are there specific technologies you’re eager to explore or implement at Noom to advance digital health solutions?
Dr. David Luu: The longevity space lends itself naturally to the use of emerging and precision tech, and Noom is committed to bringing the latest health technology to its patients. In particular, Noom has done an incredible job at integrating AI into its programs, and I’m looking forward to being a part of accelerating those efforts as it strategically makes moves to capture the longevity space.
Slice of Healthcare: With your experience providing cardiac care in underserved regions through The Heart Fund, do you foresee opportunities to extend Noom’s preventive health initiatives to global, underserved populations?
Dr. David Luu: I’m impressed with Noom’s commitments to democratizing health solutions, as well as their work with public and private institutions that have identified obesity, metabolic health, and women’s issues as critical for advancement. As someone that has spent 20 years treating and preventing disease in developing countries, I’m excited to explore the synergies between my nonprofit work and Noom’s mission. The beauty of health tech is its scalability – and together, we have the potential to impact millions of lives.
Insights from Geoff Cook, CEO of Noom
Slice of Healthcare: Dr. Luu brings a unique blend of clinical expertise and health-tech entrepreneurship to Noom’s board. What specific areas of Noom’s strategy or product development do you anticipate Dr. Luu having the most impact on?
Geoff Cook: Longevity is the future of healthcare. Every doctor should be a longevity doctor. We see Noom as the front door to healthy aging and longevity. Noom is well positioned given its significant experience driving healthy habit adoption with a unique psychology-based approach and also given its successful entry into the GLP-1 market. We have recently made two big hires to further enhance our longevity expertise and drive this critical growth area for us: Dr. Luu, a doctor and founder of LongevityDocs, and our new Chief Medical Officer Dr. Jeffrey Egler, a longevity doctor with expertise in healthy aging and lifestyle science.
Slice of Healthcare: As Noom continues to focus on chronic disease prevention and longevity care, how will Dr. Luu’s presence on the board help shape or accelerate these initiatives?
Geoff Cook: As we look to the future, we know that GLP-1s are going to play an important role in helping people live better longer – not just helping them lose weight or control diabetes. There is increasingly strong and emerging evidence that points to GLP-1s playing a role in improving multiple facets of health and wellness, including:
- Cardiovascular Health: Studies show reduced major adverse cardiovascular events – fewer heart attacks, strokes, and cardiovascular deaths in high-risk patients.
- All-Cause Mortality: Treatment with GLP-1 agonists modestly lowers overall mortality in patients with cardiometabolic risk. A 2021 meta-analysis of outcome trials found about a 12% reduction in all-cause death with GLP-1 RAs compared to placebo.
- Renal & Liver Health: GLP-1 agonists confer renal benefits, slowing the progression of kidney disease.
- Liver Health (NASH): Beyond diabetes, GLP-1 therapies improve non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
- Neuroprotection: Emerging evidence suggests GLP-1 analogs may benefit cognitive health. Recent human studies associate GLP-1 RA treatment with a significantly lower incidence of dementia and cognitive impairment in type 2 diabetics. A 2025 systematic review reported substantially reduced odds of Alzheimer’s and related dementias among patients on GLP-1 therapies.
As a longevity expert, Dr. Luu and Dr. Egler will have important voices in how we evolve our existing products and launch new ones to capture the broader longevity market.
Slice of Healthcare: Noom’s mission is to empower everyone, everywhere to live better longer. With Dr. Luu’s experience in providing medical care to underserved communities, are there plans to further expand Noom’s outreach to global or lower-income populations?
Geoff Cook: We have significant launches planned later this year to further drive access to Noom among lower-income populations, who are critically important to us and our mission. This year, we are very focused on the “everyone, everywhere” aspect of our mission statement. Noom differentiates from competitors with a focus on motivation.
People come to Noom knowing they should eat healthier and move more, but the issue is doing it when life gets in the way. Noom is motivation our members can count on and health that they can see, in the mirror, on the scale, and even in their blood biomarkers. Noom delivers results our members can feel in their vitality, confidence, and focus. We are creating Noom as a destination for everyone, everywhere, regardless of income.
Slice of Healthcare: How do you plan to leverage Dr. Luu’s extensive global health network to potentially introduce new programs or initiatives at Noom?
Geoff Cook: I’m excited to attend Dr. Luu’s Longevity Medicine summit in Cannes this summer. We have a talented team of engineers and product developers at Noom who are actively building the future of longevity medicine. Dr. Luu’s network and expertise, as well as Dr. Egler’s hands-on guidance, will be critical to Noom’s achievement of its vision to add a decade of healthspan for every member, through a combination of healthy habits and pharmacological intervention, if indicated.
Slice of Healthcare: The GLP-1 space seems crowded right now. How are you planning to differentiate from others as you move from weight loss to longevity?
Geoff Cook: Noom already has the infrastructure in place to deliver big on longevity for consumers: We don't just provide a program, and we don’t just provide medication – we provide increased motivation, improved behaviors and habits, we provide personalized medication, and we provide social connection and support. These critical elements of Noom have already been leading to the best health outcomes for patients for years – and these are also the same elements that are the essence of longevity. Said differently, we are the only company that is already executing on what it takes to bring longevity to consumers at scale.
Slice of Healthcare: How is healthcare going to change in the next 5-10 years, and where will Noom be in that?
Geoff Cook: Noom is a company that is built on being able to make smart predictions about the future of healthcare, and we are predicting that longevity is the future of consumer healthcare. There are a few companies out there right now that are doing longevity in high-cost, very inaccessible ways – for example, expensive scans, executive physicals, highly priced supplements, and so on. Noom has mastered the art of taking healthcare solutions that were once only available to the very sick or the very elite and bringing them to everyone. We are deeply engaged in this work as it comes to longevity medicine and we are tremendously excited about being able to share longevity tools with the masses very soon.
Conclusion
Dr. David Luu’s appointment to Noom’s Board marks a significant step forward in the democratization of longevity medicine and digital health. His unique blend of clinical expertise, technology integration, and global outreach aligns perfectly with Noom’s mission to empower everyone, everywhere to live better longer. Together, they’re poised to continue to redefine how we think about aging, health, and vitality.
